Jiang Wu

ORCID: 0000-0001-8434-5257 · 2 papers in corpus
review 2026
Biomarker research ·doi:10.1186/s40364-026-00908-0

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a paradigm-shifting therapeutic strategy in oncology, demonstrating significant synthetic lethality in tumors characterized by homologous recombination deficiency. Due to their …

review 2018
BioMed research international ·doi:10.1155/2018/2369430

In the most recent publications on Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, the uterine remnants and ovaries in patients may develop uterine remnant leiomyoma, adenomyosis, or ovarian tumor, and this can lead to problems in different…